Siri A. Urquhart

Siri A. Urquhart

Auto-generated profile, based on publicly available information

Siri A. Urquhart

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
SUSiri A Urquhart
Siri A Urquhart
BCBryce P Comstock
Bryce P Comstock
MJMauricio F Jin
Mauricio F Jin
CDCourtney N Day
Courtney N Day
JEJohn E Eaton
John E Eaton
NCNayantara Coelho-Prabhu
Nayantara Coelho-Prabhu
Background: Ileal pouch–anal anastomosis (IPAA) is the standard restorative procedure following proctocolectomy in patients with inflammatory bowel disease (IBD) who require colectomy. However, removal of the diseased colon does not eliminate the risk of pouch neoplasia. We aimed to assess the incidence of pouch neoplasia in IBD patients following IPAA. Methods: All patients at a large tertiary center with International Classification of Diseases–Ninth Revision/International Classification of Diseases–Tenth Revision codes for IBD who underwent IPAA and had subsequent pouchoscopy were identified using a clinical notes search from January 1981 to February 2020. Relevant demographic, clinical, endoscopic, and histologic data were abstracted. Results: In total, 1319 patients were included (43.9% women). Most had ulcerative colitis (95.2%). Out of 1319 patients, 10 (0.8%) developed neoplasia following IPAA. Neoplasia of the pouch was seen in 4 cases with neoplasia of the cuff or rectum seen in 5 cases. One patient had neoplasia of the prepouch, pouch, and cuff. Types of neoplasia included low-grade dysplasia (n = 7), high-grade dysplasia (n = 1), colorectal cancer (n = 1), and mucosa-associated lymphoid tissue lymphoma (n = 1). Presence of extensive colitis, primary sclerosing cholangitis, backwash ileitis, and rectal dysplasia at the time of IPAA were significantly associated with increased risk of pouch neoplasia. Conclusions: The incidence of pouch neoplasia in IBD patients who have undergone IPAA is relatively low. Extensive colitis, primary sclerosing cholangitis, and backwash ileitis prior to IPAA and rectal dysplasia at the time of IPAA raise the risk of pouch neoplasia significantly. A limited surveillance program might be appropriate for patients with IPAA even with a history of colorectal neoplasia.

1 April 2021 in Crohn's & Colitis 360
Verified
Journal Article
Open access
PDF file
SUSiri A Urquhart
Siri A Urquhart
KQKevin P Quinn
Kevin P Quinn
KRKarthik Ravi
Karthik Ravi
ELEdward V Loftus
Edward V Loftus
Background: The clinical characteristics and treatment outcomes in patients with eosinophilic esophagitis (EoE) and inflammatory bowel disease (IBD) have not been extensively investigated. Methods: We determined treatment outcomes and frequencies of disease-related complications in patients with EoE and IBD. Results: Among 69 patients who met inclusion criteria, 39 (56.5%) had a diagnosis of Crohn disease. Clinical and histologic response rates to proton pump inhibitors and topical steroids were 25.9% and 24.4%, respectively. Conclusions: Lower than expected clinical and histologic response rates for EoE suggest the combination of EoE and IBD is a medically refractory phenotype with more difficult to treat EoE.

15 June 2024 in Gastro Hep Advances
Verified
Journal Article
Open access
SUSiri A. Urquhart
Siri A. Urquhart
MEMatthew W. Ewy
Matthew W. Ewy
KFKristina T. Flicek
Kristina T. Flicek
JFJeff L. Fidler
Jeff L. Fidler
SSShannon P. Sheedy
Shannon P. Sheedy
NCNayantara Coelho-Prabhu
Nayantara Coelho-Prabhu
Segmental colitis associated with diverticulosis (SCAD) is an underrecognized disease characterized by chronic segmental inflammation surrounding colonic diverticula. SCAD is recognized as an autonomous entity, although shares similar pathogenic and therapeutic aspects to inflammatory bowel disease and may be considered a complication of diverticulitis. We aimed to characterize the clinical, endoscopic, and radiographic findings of SCAD and its potential overlap with diverticulitis and inflammatory bowel disease. All patients with suspected diagnosis of SCAD were identified using a bioinformatics search tool from January 1996 to October 2021 at our institution. Relevant demographic, clinical, endoscopic, and radiographic data were abstracted. Disease-related outcomes and radiographic characteristics were determined. Seventy-five patients with SCAD were included (48.0% female) with average age at diagnosis 62.5 years. Thirty-seven (49.3%) had a prior episode of diverticulitis. The most common presenting symptoms were abdominal pain (33.3%) and hematochezia (22.7%). Antibiotics (42.7%) and mesalamine (36.0%) were most used as first-line treatment options. Twenty (26.7%) required surgical intervention. The most common initial endoscopic finding was isolated sigmoid inflammation (86.7%). Fifty-one patients with confirmed SCAD, 72 with diverticulitis, and 12 with Crohn's disease (CD) had imaging available for review. Penetrating disease was seen in 7 (13.7%) with SCAD compared to 7 (9.7%) and 2 (16.6%) with diverticulitis and CD, respectively (P = .14). Blinded radiologists diagnosed SCAD, CD, or diverticulitis correctly in 43.8%, 8.3%, and 27.1%, respectively. SCAD should be considered when isolated sigmoid colon inflammation is seen on cross-sectional imaging. Penetrating disease is not a specific radiologic feature for either SCAD or diverticulitis. Further prospective studies are needed to correlate imaging characteristics with endoscopic findings to better describe radiographic features in SCAD.

5 July 2024 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
SUSiri A Urquhart
Siri A Urquhart
VCVictor G Chedid
Victor G Chedid
SKSunanda V Kane
Sunanda V Kane
Lay Summary: Upadacitinib, a selective JAK-1 inhibitor, was used as rescue therapy for ulcerative colitis in the setting of pregnancy following use of mesalamine, vedolizumab, infliximab, and corticosteroids. This resulted in an uncomplicated live full birth without need for surgical intervention.

20 August 2020 in Case Reports in Gastrointestinal Medicine
Verified
Journal Article
Open access
PDF file
SUSiri A. Urquhart
Siri A. Urquhart
NCNayantara Coelho-Prabhu
Nayantara Coelho-Prabhu
Heterotopia is the presence of normal physiologic tissue in an atypical location. Gastric heterotopia has been described in various locations throughout the gastrointestinal tract, including the small intestine. Gastric heterotopia of the small intestine typically is asymptomatic but may present in several ways with symptoms of obstruction, bleeding, perforation, intussusception, or pain. However, gastric heterotopia is rare beyond the duodenum except for its frequent association with Meckel’s diverticulum. This entity should be considered in the differential diagnosis of polypoid lesions presenting with symptoms of bleeding or obstruction especially in younger patients. We present a case of gastric heterotopia of the jejunum in a patient with a prior history of Meckel’s diverticulectomy after he presented with obstructive symptoms. His symptoms improved following resection of two jejunal polyps via antegrade double-balloon assisted enteroscopy with fluoroscopy. On histopathlogical examination, findings were consistent with gastric heterotopia. This case highlights the importance of considering gastric heterotopia in the differential diagnosis of polypoid lesions located beyond the ligament of Treitz in younger patients presenting with obstructive symptoms.

12 March 2026 in Gastro Hep Advances
Verified
Journal Article
Open access
SUSiri A. Urquhart
Siri A. Urquhart
PRPrajith Raj Ramesh
Prajith Raj Ramesh
SKSunanda V. Kane
Sunanda V. Kane
LRLaura E. Raffals
Laura E. Raffals
ELEdward V. Loftus
Edward V. Loftus
NCNayantara Coelho-Prabhu
Nayantara Coelho-Prabhu
Primary sclerosing cholangitis (PSC) is an immune-mediated liver disease frequently associated with inflammatory bowel disease (IBD). PSC-IBD represents a distinct phenotype with extensive colitis, right-sided predominance, and elevated colorectal cancer risk. We aimed to evaluate the impact of oral vancomycin on clinical, endoscopic, and histologic findings of IBD and both intestinal and liver biomarkers of these patients. A retrospective study was performed among patients with PSC-IBD treated with oral vancomycin from January 1992 to August 2024. Data collected included demographics, disease characteristics, prior therapies, vancomycin use and dosing, clinical response, laboratory markers, endoscopic, and histologic activity of the colon. Vancomycin-free survival was estimated using Kaplan–Meier analysis. Among 90 patients (80% ulcerative colitis) included, the median age at PSC diagnosis was 17.4 years. Clinical improvement related to intestinal inflammation was observed in 50%, and 12.2% achieved remission. Endoscopic inactivity increased from 18.8% to 60.3%, and histologic inactivity or mild disease rose from 57.7% to 86.2%. Median change in serum alkaline phosphatase was −48.5 U/L (P = .5681), and median fecal calprotectin decreased from 485 μg/g to 67.7 μg/g. Clinical, endoscopic, and biochemical improvements were observed across low- (≤500 mg/d) and high-dose (>500 mg/d) groups. Five-year vancomycin-free survival was comparable between dose groups. Oral vancomycin was associated with meaningful improvements in clinical, endoscopic, histologic, and biomarker outcomes in intestinal inflammation of patients with PSC-IBD, with durable responses across different doses. These findings support vancomycin as a potential disease-modifying therapy, warranting prospective randomized trials to establish efficacy, optimal dosing, and long-term safety.